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INTRODUCTION 
Disorders of the thyroid include both 
overt and subclinical hypothyroidism 
and hyperthyroidism. Subclinical thyroid 
dysfunction is common among older people, 
characterised by serum thyroid-stimulating 
hormone (TSH) outside the reference range, 
in association with serum thyroid hormone 
(free thyroxine [FT4] and triiodothyronine 
[FT3]) concentrations within the reference 
range.1–3 Both subclinical thyroid states are 
of limited clinical relevance. In overt thyroid 
disease states clinicians are generally more 
concerned about hypothyroidism, because 
onset is often non-specific and insidious, so 
the diagnosis is often missed. In contrast, 
hyperthyroidism will normally present with 
less common symptoms and be diagnosed 
promptly.
Within the UK, systematic screening is 
not recommended, partly because ‘The 
natural history of thyroid dysfunction 
remains unclear’.4 Because there is also 
uncertainty over management of subclinical 
disease, current practice is both variable 
and potentially suboptimal or excessively 
costly.5–7 
Recommendations for how often thyroid 
function tests (TFTs) should be repeated 
after a previously normal or subclinical test 
result are lacking. The annual estimated 
cost of TFTs in the UK is £30 million, with 
the majority originating in primary care.5,8–9 
Recent work undertaken by the authors 
suggests that, annually in UK general 
practice, TFTs are requested for around 
30% of older patients without overt thyroid 
dysfunction (unpublished data). Available 
evidence suggests that primary care 
physicians (PCPs) repeatedly request TFTs 
in this patient group, in response to vague 
symptoms, previously mildly abnormal 
tests, or as part of other routine care 
monitoring.8 Few studies have explored the 
natural history of thyroid dysfunction, or the 
value of a single TFT within a primary care 
population. One small single-site primary 
care-based study followed 73 patients with 
subclinical hypothyroidism for 12 months, 
reporting that 17.8% developed overt 
disease and 5.5% reverted to a euthyroid 
state.1 Follow-up of the Whickham cohort 
identified increased odds of development 
of overt disease if an elevated TSH had 
previously been reported, but the 20-year 
interval used in this study and all-age 
cohort makes application of findings to an 
older population difficult.10 
Secondary care studies are conflicting, 
with one study reporting an incidence of 9.9 
overt cases per 100 patient–years, and a 
study with longer follow-up suggesting an 
annual incidence of 5.6, although the female-
only population derived from secondary 
care limits generalisability.11,12 A further 
female-only cohort study of 252 individuals 
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Background
Thyroid function tests (TFTs) are among the 
most requested tests internationally. However, 
testing practice is inconsistent, and potentially 
suboptimal and overly costly. The natural history 
of thyroid function remains poorly understood. 
Aim
To establish the stability of thyroid function over 
time, and identify predictors of development of 
overt thyroid dysfunction.
Design and setting
Longitudinal follow-up in 19 general practices 
in the UK.
Method
A total of 2936 participants from the 
Birmingham Elderly Thyroid Study (BETS 1) 
with a baseline TFT result indicating euthyroid 
or subclinical state were re-tested after 
approximately 5 years. Change in thyroid-
stimulating hormone (TSH), free thyroxine (FT4), 
and thyroid status between baseline and follow-
up was determined. Predictors of progression 
to overt dysfunction were modelled.
Results
Participants contributed 12 919 person-years; 
17 cases of overt thyroid dysfunction were 
identified, 13 having been classified at baseline 
as euthyroid and four as having subclinical 
thyroid dysfunction. Individuals with subclinical 
results at baseline were 10- and 16-fold 
more likely to develop overt hypothyroidism 
and hyperthyroidism, respectively, compared 
with euthyroid individuals. TSH and FT4 
demonstrated significant stability over time, 
with 61% of participants having a repeat TSH 
concentration within 0.5 mIU/L of their original 
result. Predictors of overt hypothyroidism 
included new treatment with amiodarone 
(odds ratio [OR] 92.1), a new diagnosis of atrial 
fibrillation (OR 7.4), or renal disease (OR 4.8). 
Conclusion
High stability of thyroid function demonstrated 
over the 5-year interval period should 
discourage repeat testing, especially when a 
euthyroid result is in the recent clinical record. 
Reduced repeat TFTs in older individuals is 
possible without conferring risk, and could 
result in significant cost savings.
Keywords
ageing; general practice; primary health care; 
subclinical thyroid dysfunction; symptoms; 
thyroid function test.
L Roberts, PhD, professor and deputy dean, 
Medical School, University of Warwick, Warwick. 
D McCahon, PhD, senior researcher, Centre for 
Academic Primary Care, University of Bristol, 
Bristol. O Johnson, MBChB, house officer, 
Countess of Chester Hospital, Chester. MS Haque, 
PhD, statistician, Institute of Applied Health 
Research; J Parle, MD, professor, Institute of 
Clinical Sciences, University of Birmingham, 
Birmingham. FDR Hobbs, FMedSci, Nuffield 
professor and head, Department of Primary Care 
Health Sciences, University of Oxford, Oxford.
Address for correspondence
FD Richard Hobbs, Nuffield Department of 
Primary Care Health Sciences, Radcliffe Primary 
Care Building, Radcliffe Observatory Quarter, 
Woodstock Road, University of Oxford, Oxford 
OX2 6GG, UK. 
Email: richard.hobbs@phc.ox.ac.uk 
Submitted: 9 April 2018; Editor’s response:  
4 May 2018; final acceptance: 10 June 2018.
©British Journal of General Practice
This is the full-length article (published online 
29 Aug 2018) of an abridged version published in 
print. Cite this version as: Br J Gen Pract 2018;  
DOI: https://doi.org/10.3399/bjgp18X698861
Lesley Roberts, Deborah McCahon, Oliver Johnson, M Sayeed Haque, James Parle 
and FD Richard Hobbs
Stability of thyroid function in older adults:
the Birmingham Elderly Thyroid Study 
e718  British Journal of General Practice, October 2018 
referred for elevated TSH reported a similar 
progression, with 19% requiring treatment 
for overt dysfunction or persistent elevated 
TSH (>10 mIU/L) over a 5-year interval.13 This 
Brazilian study was conducted in a region 
of iodine intake inadequacy, and relevance 
to the UK may be lacking. Although both 
populations and biochemical definitions of 
thyroid dysfunction differ, the much lower 
annual incidence reported in secondary care 
populations compared with the primary care 
study indicates more evidence is needed to 
identify predictors of overt disease outside 
of the secondary care setting. 
Evidence for the progression of 
subclinical hyperthyroidism is similarly 
lacking. Sawin et al14 reported that none 
of the 33 subclinically hyperthyroid patients 
they followed up for 4 years developed overt 
disease, and similar findings are reported 
by Woeber,15 with only one of 16 patients 
followed developing overt disease. Although 
these findings demonstrate consistency, 
numbers are small and a recent expert panel 
review concluded that there was insufficient 
evidence to comment on the natural history 
of subclinical hyperthyroidism.5 
This study aimed to address some of 
the important gaps in the evidence base, 
namely to:
• determine incidence of subclinical 
thyroid dysfunction in an older primary 
care population previously shown to be 
euthyroid; 
• establish the proportion of patients with 
subclinical thyroid dysfunction who revert 
to a euthyroid state, experience persisting 
subclinical dysfunction, or develop overt 
disease; 
• evaluate within-person variation in TSH 
and FT4 concentrations over a 5-year 
interval; and 
• identify predictors of progression to overt 
hyper/hypothyroidism.
METHOD 
Background to the Birmingham Elderly 
Thyroid Study (BETS 1)
The present study comprises follow-up 
of the BETS 1 cohort, a screening study 
of 5881 patients aged >65 years from 
20 practices representative of the UK, 
conducted between 2002 and 2004.16–19 
Thyroid function tests measured TSH and 
FT4. Measurement of FT3 was undertaken 
as dictated by routine laboratory protocol. 
Practice recruitment 
A total of 19 of the original 20 practices in 
the BETS 1 study agreed to participate. 
Inclusion criteria 
Patients identified in BETS 1 as having 
thyroid function results within normal or 
subclinical ranges were included in this 
study. 
A euthryroid status was defined as both 
TSH and FT4 being within ranges indicated 
in Table 1. Subclinical hypothyroidism 
and hyperthyroidism were defined as FT4 
in range, and TSH being above or below 
reference range, respectively.
Exclusion criteria 
BETS 1 participants were excluded if:
• classification of thyroid status was not 
possible, or if they had overt thyroid 
dysfunction at baseline;
• they were recruited to the active treatment 
arm of the randomised controlled trial 
(RCT) embedded within BETS 1;17 
• the responsible clinician deemed contact 
inappropriate; or
How this fits in
Thyroid tests are commonly requested in 
the routine care of older adults. Subclinical 
thyroid dysfunction is a relatively common 
biochemical finding among older patients. 
Current practice for the management of 
a single test indicating mildly abnormal 
thyroid dysfunction in the older population 
is variable, and potentially suboptimal and 
overly costly. This large, population-based 
survey demonstrates significant stability 
in thyroid function over a period of up to 
5 years in the older population, with 96% of 
individuals who were euthyroid at baseline 
remaining so, and <0.5% developing an 
overt hyperthyroid or hypothyroid status. 
Based on this evidence, routine repeat 
thyroid function testing among older 
individuals who have a recent (within 
5 years) euthyroid result in their clinical 
record is not advised, unless clinically 
indicated. 
Table 1. Reference ranges for thyroid function assays with their 
associated intra-assay coefficient of variation
  Intra-assay coefficient of variation, 
Test Reference range associated range (95% CI)
Thyroid-stimulating hormone (TSH) 0.3–4.5 mlU/L 1.5% (0.5 to 33.0 mlU/L)
Free thyroxine (FT4) 10–22 pmol/L 2.0–2.5% (9.0 to 66.0 pmol/L)
Free triiodothyronine (FT3) 3.1–6.8 pmol/L 2.0–3.5% (4.0 to 21.0 pmol/L)
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• they were unable or unwilling to give 
informed consent.
Study procedure
All eligible patients were sent an invitation 
letter, patient information sheet, and 
response return slip, after receipt of 
which screening appointments were 
organised at their usual surgery. TFTs for 
BETS 2 occurred over a 9-month period, 
approximately 5 years after the initial 
screening.
Case note evaluation
Data on diagnoses and treatment, including 
known confounders such as amiodarone 
(which comprises 37% iodine), were 
collected from primary care records. 
All significant medical diagnoses were 
categorised in accordance with recognised 
major disease groups, as reported in 
BETS 1.16
The results of the TFTs immediately 
prior to commencement of treatment were 
extracted for participants having thyroid 
surgery, radioiodine therapy, or starting 
antithyroid drugs and thyroxine replacement 
therapy in the interval period. If one or both 
measurements had not been conducted 
immediately prior to initiation of treatment, 
medical records were reviewed to ascertain 
reason for commencement of therapy, and 
to enable classification of thyroid status.
Measurement and categorisation of 
thyroid function 
TFTs were measured by 
electrochemiluminescent immunoassays 
(Roche E170, Roche Diagnostics, UK). 
The TSH assay was calibrated against the 
second International Reference Preparation 
80/558 (lower limit of reporting 0.02 mIU/L, 
manufacturer’s quoted mean functional 
sensitivity 0.014 mIU/L). Laboratory 
reference ranges are reported in Table 1. 
Changes in the assays used to measure 
TSH, FT4, and FT3 occurred between the two 
studies.16 In parallel with this, a change to 
the standard reference ranges for TSH, FT4, 
and FT3 occurred. To enable comparison 
across the two timepoints, a correction 
factor was applied to the baseline TFT 
results, and subsequent reclassification of 
thyroid status was undertaken before data 
were compared across the time interval.
Thyroid status was classified as 
euthyroid, subclinically hypothyroid, overtly 
hypothyroid, subclinically hyperthyroid, or 
overtly hyperthyroid based on the reference 
ranges reported in Table 1. 
Follow-up contribution in terms of patient 
years at risk was calculated for all subjects 
as the time interval between initial and 
follow-up screen. Those receiving thyroid 
function treatment were classified based 
on the results of the TFT immediately prior 
to commencement of treatment, and their 
contribution censored at this point. 
Primary analysis 
Incidence was calculated as number of 
cases divided by number of person-years 
at risk. Risks of developing disease were 
calculated, and risks compared for groups 
who were categorised as euthyroid and 
subclinical at BETS 1. Sensitivity analysis 
was performed reclassifying all patients 
who commenced therapy during the 
interval period as having overt thyroid 
dysfunction (for example, overt hyper- or 
hypothyroidism based on treatment given) 
and re-running analyses. 
Binary logistic regressions were 
performed to identify predictors of 
development of overt hyper/hypothyroidism. 
The forward stepwise logistic regression 
(LR) method was used to identify variables 
with a significance level of 5% for inclusion 
and 10% for removal. Two additional 
variables were created, one to indicate 
subclinical thyroid status at BETS 1 and the 
other to indicate whether BETS 1 thyroid 
function status had been reclassified due 
to the application of the laboratory-defined 
correction factors. In total, 31 variables 
were available for construction of r models, 
including medical conditions (classed as 
absent/pre-existing/new [occurring in the 
interval between studies]), amiodarone 
use, alcohol intake, smoking status, family 
history of thyroid dysfunction, age, and 
deprivation measure (Index of Multiple 
Deprivation [IMD] 2004 score).20 Analyses 
were undertaken using SPSS (version 15.0).
Exploratory analysis
To explore stability of TSH and FT4 over 
time, the change in both measures between 
BETS 1 and BETS 2 was calculated for each 
participant, and BETS 1 values plotted 
against BETS 2 values to explore within-
person change.
RESULTS
Eligibility for follow-up
Overall, 103 BETS 1 participants were 
ineligible for follow-up (Figure 1). A further 
1335 were deceased or excluded prior to 
invitation. Just under 50% of the BETS 1 
cohort (n = 2936) fulfilled the inclusion 
criteria and attended for follow-up. Those 
available for follow-up demonstrated 
a statistically significant difference in 
deprivation scores and age compared with 
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those not available for follow-up. 
The screened cohort had baseline IMD 
scores indicative of marginal greater 
affluence (mean IMD 21.65 versus 25.65) 
and were, on average, 1.82 years younger. 
This difference is likely to be attributable to 
greater mortality in older and less affluent 
participants, but given the large sample 
and 5-year follow-up period of an older 
adult cohort these difference are unlikely to 
impact findings.
Population characteristics
Age ranged from 68.7–96.4 years, with a 
5881
Original
cohort
103 Not
eligible for
follow-up
5778
Status
verified
51 Received
active therapy
in
BETS 1 RCT
1335
Excluded
9
Unclassified
TFT
501
Deceased
15 Overt
hyperthyroid
dysfunction
453 Not
registered
27 Overt
hypothyroid
dysfunction
184 Practice
not
participating
1 Error in
DOB data
leading to
ineligibility
197 GP
exclusions
28
Inconvenient
clinic
dates and
times
24 Were too
unwell
to attend
72
No longer
wished to
take part
125 Unable
to book
3104
Accept a clinic
appointment
87
Did not attend
12
Unable or not
wishing to
consent
3005
Attend
screening
clinic
61 No TFT
or
treatment
censor
date
7 Other
(6 thyroid
surgery and
1 missing
data)
1
Unclassified
TFT
2936
Included
in the
analysis
4443
Invited
3229
Agree to
re-screen
353
No
response
793 Not
wishing to
take part
37 No
longer
registered
31 Deceased
1 Deceased
between
response to
invite and clinic
appointment
Figure 1. Consort diagram. BETS 1 = Birmingham 
Elderly Thyroid Study 1. DOB = date of birth. RCT = 
randomised controlled trial. TFT = thyroid function 
tests.
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mean of 76.9 years (standard deviation [SD] 
5.03), and 49% were female. Socioeconomic 
status ranged from 3.16 (most affluent) to 
74.4 (least affluent), mean IMD score 21.79 
(SD 15.14). 
Overall, 92.3% (2709/2936) were 
classified as euthyroid, 1% (n = 29) 
subclinically hyperthyroid, 6.2% (n = 181) 
subclinically hypothyroid, 0.3% (n = 8) as 
overtly hyperthyroid and 0.3% (n = 9) overtly 
hypothyroid. In addition, 1.8% (53/2936) had 
a thyroid diagnosis or treatment in the 
interim period, and were classified based 
on the TFT immediately prior to treatment 
commencement. 
Status change over time
Overall, 95.5% (2644/2768, 95% 
confidence interval [CI] = 94.7 to 96.3%) 
of the individuals classified as euthyroid 
at baseline retained euthyroid status at 
follow-up. Six (0.2%, 95% CI = 0.1 to 0.5%) 
classified as euthyroid at baseline had 
developed overt hypothyroidism, and seven 
(0.3%, 95% CI = 0.1 to 0.5%) had developed 
overt hyperthyroidism. Only 3.5% (98/2768, 
95% CI = 2.9 to 4.3%) had follow-up results 
indicative of a change from euthyroid to 
subclinical hypothyroidism, and 0.5% 
(13/2768, 95% CI = 0.3 to 0.8%) to subclinical 
hyperthyroidism (Table 2). 
Of the 25 individuals classified as 
subclinically hyperthyroid at baseline, 16 
(64.0%, 95% CI = 42.5 to 82.0%) retained this 
classification, eight (32.0%, 95% CI = 15.0 
to 53.5%) reverted to euthyroid status, and 
one individual (4.0%, 95% CI = 0.1 to 20.4%) 
developed overt hyperthyroidism. A similar 
proportion, 58.0% (83/143, 95% CI = 49.5 
to 66.2%), classified as being subclinically 
hypothyroid at baseline remained so, 40.0% 
(n = 57, 95% CI = 31.8 to 48.4%) reverted 
to euthyroid status, whereas 2.0% (n = 3, 
95% CI = 0.4 to 6.0%) developed overt 
hypothyroidism (Table 2).
Sensitivity analysis 
Because therapy may have disrupted natural 
history and dysfunction progression, all 
treated cases were re-categorised as having 
overt thyroid dysfunction. The total number 
of cases of assumed overt hypothyroidism 
therefore increases to 51 (26 being 
euthyroid and 25 subclinical at baseline), 
suggesting that a maximum of 1.7% may 
have developed overt hypothyroidism 
compared with the 0.3% estimate based 
on TFT results alone. The total number of 
cases of overt hyperthyroidism remains the 
same, because in all cases therapy was 
commenced based on TFT results in the 
overt range. 
Cases of overt dysfunction
Overall, 2936 participants contributed 
12 919 person-years for analysis. The risk 
Table 2. Thyroid status at baseline and follow-upa
 Follow-up (BETS 2) status (1 unclassified)
  Overt Subclinical Euthyroid, % Subclinical Overt 
  hypothyroid, % hypothyroid, % n = 2709 hyperthyroid, % hyperthyroid, % 
 n = 2936 n = 9 (0.3%) n = 181 (6.2%) (92.3%) n = 29 (1.0%) n = 8 (0.3%)
 Subclinical hypothyroid  3  83  57  
Baseline (n = 143) (2.0)  (58.0)  (40)
 0 0
(BETS 1) Euthyroid 6 98  2644  13 7 
status (n = 2768) (0.2) (3.5)  (95.5)  (0.5) (0.3)
 Subclinical hyperthyroid  
0 0
 8  16  1 
 (n = 25)   (32.0)  (64.0)  (4.0)
aShaded cells indicate no status change over the screening interval.
Table 3. Logistic regression: factors associated with development of 
hypothyroidism and associated likelihooda
Variable Coefficient P-value OR 95% CI 
Baseline TSH 0.38 0.001 1.46 1.17 to 1.81
Baseline FT4 –0.86 <0.001 0.42 0.27 to 0.66
Newb amiodarone prescription 4.61 0.001 92.1 5.64 to 1501.39
Newb AF diagnosis 2.00 0.012 7.41 1.56 to 35.14
Newb renal disease diagnosis 1.57 0.044 4.81 1.04 to 22.22
aIn all, 31 variables were available for construction of logistic regression models, comprising 22 disease categories, 
amiodarone use, alcohol use, smoking status, family history of thyroid dysfunction, age, sex, IMD score, and 
baseline TSH and FT4. Seven disease groups and family history were removed to maximise the dataset available 
for analysis where data were missing for ≥1% of the population. The forward stepwise method was used with a 
significance level of 5% for variable inclusion, and 10% for variable removal. Eight variables were entered to the final 
model, though existing (at baseline) diagnoses of AF, renal disease, or amiodarone use did not make a significant 
contribution to the final model. bPrescription or diagnosis occurring for the first time after the initial baseline 
screening episode. AF = atrial fibrillation. FT4 = free thyroxine. IMD = Index of Multiple Deprivation. OR = odds ratio. 
TSH = thyroid stimulating hormone. 
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of developing overt hypothyroidism in the 
subclinical hypothyroid group was 51.5 per 
10 000 person-years at risk (95% CI = 38.8 
to 67.1), compared with 4.9 (95% CI = 1.6 
to 10.2) per 10 000 person-years at risk in 
the euthyroid group, making the subclinical 
group 10 times more likely to develop overt 
hypothyroid dysfunction. 
Sensitivity analyses increase risk for an 
individual with a subclinical hypothyroid 
status to 20 times that for a euthyroid 
individual 429.5 (95% CI = 390.3 to 471.9) 
versus 21.3 (95% CI = 13.8 to 32.1) per 10 000 
person-years at risk, respectively. It is noted 
that true risk is likely to be magnified in 
sensitivity analyses due to inclusion of 20 
individuals who were euthyroid at baseline 
but treated with thyroxine during the interval 
period based on a subclinical result. 
The risk of an individual with a subclinical 
hyperthyroid status developing overt 
hyperthyroidism was approximately 16 
times greater than that of an individual with 
a euthyroid status — 95.4 (95% CI = 7.8 to 
116.1) versus 5.7 (95% CI = 2.2 to 11.7) per 
10 000 person-years at risk, respectively. 
Predictors of development of overt 
thyroid dysfunction
Given the low number of events (overt thyroid 
disease), it was not possible to produce 
a robust model to predict development 
of overt dysfunction. However, given that, 
to achieve sufficient events for modelling, 
>14 000 individuals would require follow-up 
(from a 28 000 baseline population, based 
on the authors’ follow-up), the authors 
have provided a cautious model based 
on available data to identify factors that 
appear to increase risk of development of 
hypothyroidism (Table 3). Individuals with 
higher TSH or lower FT4 values at baseline 
are at greatest risk of development of 
overt hypothyroid status. Later diagnoses 
of atrial fibrillation (AF) or renal disease, 
or commencement of amiodarone, also 
increase the likelihood of progression.
The model constructed to predict 
development of hyperthyroidism failed to 
demonstrate any predictors, which is not 
surprising given the very low event rate.
Change in TSH and T4 
Change in TSH between BETS 1 and 
BETS 2 was calculated and explored using 
an arbitrary definition of a shift of ≥0.5 
units being classified as ‘change’. Using 
this definition, 61% of participants showed 
no change between BETS 1 and BETS 2. 
Removal of outliers further demonstrates 
equal numbers of individuals experiencing 
an increase and decrease in TSH between 
timepoints, and, for the majority, TSH 
remains relatively stable (Figure 2). 
Change in FT4 was calculated based on 
a definition of change as ≥1.0 unit — 39.6% 
(n = 1162) of participants showed no change, 
with very few individuals demonstrating 
large shifts in FT4 (Figure 3). 
DISCUSSION
Summary 
This large population-based study provides 
the most comprehensive data yet on the 
long-term dynamics of thyroid function 
among older patients in primary care. The 
prevalence of subclinical hypothyroidism 
in this study population was 6.2%, similar 
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Figure 2. Frequency graphs of change in TSH during 
the period of follow-up (approximately 5 years). 
TSH = thyroid-stimulating hormone.
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to that reported in smaller studies.21 
Subclinical hyperthyroidism was less 
common, with just 1% of individuals being 
affected. BETS 2 confirms the incident 
findings of BETS 1, that subclinical thyroid 
dysfunction is a relatively common 
biochemical finding among older patients, 
and therefore understanding the natural 
course of the disease is important for both 
clinicians and patients.16
This study also demonstrates significant 
stability of thyroid function in this ageing 
population over a long (mean 5-year) 
time interval, with 96% of individuals who 
were euthyroid at baseline remaining so, 
and <0.5% developing an overt hyper- or 
hypothyroid status. 
Strengths and limitations 
This is the largest study to date following the 
natural history of thyroid functioning in an 
unselected primary care cohort of more older 
adults, with >2900 individuals followed over a 
5-year period. One limitation of this study 
was that thyroid status on each occasion was 
based on a single sample. There are several 
factors that can influence the reproducibility 
of TFTs, including seasonality22 and 
intercurrent illness.23 However, any subtle 
or transient change that may have occurred 
is unlikely to have influenced the authors’ 
findings in any significant fashion due to 
the large sample size and the likelihood 
of transient fluctuations impacting at both 
timepoints. The predictive model needs to 
be interpreted with caution given low event 
rates. An automatic selection process to 
create a set of variables with the strongest 
association with the outcome was used, 
given this low event rate. However, such 
a process is data driven and may create a 
biased selection. But confidence is derived 
from the fact that all variables associated 
with development of hypothyroidism have 
strong biological plausibility.
Comparison with existing literature 
Of those individuals classified as subclinically 
hypothyroid at baseline, only 2% progressed 
to overt hypothyroidism, which is lower than 
has been previously reported.24 This study 
demonstrated 40% of such patients revert 
to euthryoid status, which is in line with 
the 15–65% estimate by Somwaru et al,25 
and the majority of those with subclinical 
hypothyroidism at baseline retain a 
subclinical state despite the long screening 
interval. Similarly, just 4% of those who 
were subclinically hyperthyroid at baseline 
developed overt hyperthyroidism. 
To further support stability over time, 
the authors demonstrate here that most 
individuals (61%) had almost no change in 
TSH (≤0.5 mIU/L), with equal numbers of 
individuals experiencing either increasing 
or decreasing TSH. This contrasts with 
findings from previous work that suggests 
TSH increases with age.26 In a similar 
manner, the authors also demonstrate that 
FT4 is remarkably stable over time in older 
subjects. 
In this study, development of overt 
hypothyroid status was significantly 
more likely among individuals with a new 
diagnosis of either AF or renal disease, or 
recent commencement of amiodarone. This 
supports a previous finding that prevalence 
of subclinical hypothyroidism is higher 
among patients with chronic renal disease.27 
These factors, along with previously high–
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normal TSH or low–normal FT4, increase 
the likelihood of hypothyroid dysfunction 
and may represent triggers for repeat 
testing, although further work is needed 
to describe any benefit accrued from such 
a targeted approach. The large odds ratio, 
with wide confidence intervals, observed 
for commencement of amiodarone during 
the follow-up period (92.1, 95% CI = 5.64 to 
1501.39) should, however, be interpreted 
with caution, as it is likely an artefact of the 
very low prevalence of amiodarone use in 
the study cohort. 
Predictors of development of 
hyperthyroidism could not be determined 
from this study but, considering the low 
incidence of hyperthyroidism, there is nothing 
to support repeat testing of individuals with a 
normal test result within the previous 5 years 
to identify hyperthyroidism in the absence of 
substantive clinical signs and symptoms. 
Implications for research and practice 
This study confirms that older patients 
with subclinical thyroid dysfunction are 
only at a small relative risk of progression 
to overt dysfunction, and absolute risk is 
very low. TFTs are remarkably stable over 
extended periods and repeat routine testing 
or screening should be avoided in this 
population, particularly where a previous 
euthyroid result is reported in the clinical 
record. Considering this evidence, clinicians 
should minimise repeat TFT, unless clinically 
indicated, among older individuals who have 
a recent (within 5 years) euthyroid result in 
their clinical record. This is an important 
finding, given that almost one-third of older 
patients without overt thyroid dysfunction 
have at least one TFT performed annually 
(unpublished data).
Further research is required into whether 
there are benefits to be had from a targeted 
approach to repeat testing based on 
triggers such as a new diagnosis of AF or 
renal disease, recent commencement of 
amiodarone, and previously high–normal 
TSH or low–normal FT4.
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